Role of GPCR (mu-opioid)–receptor tyrosine kinase (epidermal growth factor) crosstalk in opioid-induced hyperalgesic priming (type II). Issue 5 (May 2018)
- Record Type:
- Journal Article
- Title:
- Role of GPCR (mu-opioid)–receptor tyrosine kinase (epidermal growth factor) crosstalk in opioid-induced hyperalgesic priming (type II). Issue 5 (May 2018)
- Main Title:
- Role of GPCR (mu-opioid)–receptor tyrosine kinase (epidermal growth factor) crosstalk in opioid-induced hyperalgesic priming (type II)
- Authors:
- Araldi, Dionéia
Ferrari, Luiz F.
Levine, Jon D. - Abstract:
- Abstract : Abstract: Repeated stimulation of mu-opioid receptors (MORs), by an MOR-selective agonist DAMGO induces type II priming, a form of nociceptor neuroplasticity, which has 2 components: opioid-induced hyperalgesia (OIH) and prolongation of prostaglandin-E2 (PGE2 )-induced hyperalgesia. We report that intrathecal antisense knockdown of the MOR in nociceptors, prevented the induction of both components of type II priming. Type II priming was also eliminated by SSP-saporin, which destroys the peptidergic class of nociceptors. Because the epidermal growth factor receptor (EGFR) participates in MOR signaling, we tested its role in type II priming. The EGFR inhibitor, tyrphostin AG 1478, prevented the induction of prolonged PGE2 -induced hyperalgesia, but not OIH, when tested out to 30 days after DAMGO. However, even when repeatedly injected, an EGFR agonist did not induce hyperalgesia or priming. A phosphopeptide, which blocks the interaction of Src, focal adhesion kinase (FAK), and EGFR, also prevented DAMGO-induced prolongation of PGE2 hyperalgesia, but only partially attenuated the induction of OIH. Inhibitors of Src and mitogen-activated protein kinase (MAPK) also only attenuated OIH. Inhibitors of matrix metalloproteinase, which cleaves EGF from membrane protein, markedly attenuated the expression, but did not prevent the induction, of prolongation of PGE2 hyperalgesia. Thus, although the induction of prolongation of PGE2 -induced hyperalgesia at the peripheralAbstract : Abstract: Repeated stimulation of mu-opioid receptors (MORs), by an MOR-selective agonist DAMGO induces type II priming, a form of nociceptor neuroplasticity, which has 2 components: opioid-induced hyperalgesia (OIH) and prolongation of prostaglandin-E2 (PGE2 )-induced hyperalgesia. We report that intrathecal antisense knockdown of the MOR in nociceptors, prevented the induction of both components of type II priming. Type II priming was also eliminated by SSP-saporin, which destroys the peptidergic class of nociceptors. Because the epidermal growth factor receptor (EGFR) participates in MOR signaling, we tested its role in type II priming. The EGFR inhibitor, tyrphostin AG 1478, prevented the induction of prolonged PGE2 -induced hyperalgesia, but not OIH, when tested out to 30 days after DAMGO. However, even when repeatedly injected, an EGFR agonist did not induce hyperalgesia or priming. A phosphopeptide, which blocks the interaction of Src, focal adhesion kinase (FAK), and EGFR, also prevented DAMGO-induced prolongation of PGE2 hyperalgesia, but only partially attenuated the induction of OIH. Inhibitors of Src and mitogen-activated protein kinase (MAPK) also only attenuated OIH. Inhibitors of matrix metalloproteinase, which cleaves EGF from membrane protein, markedly attenuated the expression, but did not prevent the induction, of prolongation of PGE2 hyperalgesia. Thus, although the induction of prolongation of PGE2 -induced hyperalgesia at the peripheral terminal of peptidergic nociceptor is dependent on Src, FAK, EGFR, and MAPK signaling, Src, FAK, and MAPK signaling is only partially involved in the induction of OIH. Abstract : We investigate the mechanisms for the induction of type II hyperalgesic priming (opioid-induced hyperalgesia and prolongation of PGE2 hyperalgesia), a form of nociceptor neuroplasticity. … (more)
- Is Part Of:
- Pain. Volume 159:Issue 5(2018)
- Journal:
- Pain
- Issue:
- Volume 159:Issue 5(2018)
- Issue Display:
- Volume 159, Issue 5 (2018)
- Year:
- 2018
- Volume:
- 159
- Issue:
- 5
- Issue Sort Value:
- 2018-0159-0005-0000
- Page Start:
- Page End:
- Publication Date:
- 2018-05
- Subjects:
- Hyperalgesic priming -- Hyperalgesia -- EGFR -- MOR -- Chronic pain
Pain -- Periodicals
Douleur -- Périodiques
Anesthésie -- Périodiques
Pain
Electronic journals
Periodicals
Electronic journals
616.0472 - Journal URLs:
- http://ovidsp.ovid.com/ovidweb.cgi?T=JS&NEWS=n&CSC=Y&PAGE=toc&D=yrovft&AN=00006396-000000000-00000 ↗
http://www.sciencedirect.com/science/journal/03043959 ↗
http://www.clinicalkey.com/dura/browse/journalIssue/03043959 ↗
http://www.clinicalkey.com.au/dura/browse/journalIssue/03043959 ↗
http://journals.lww.com/pain/pages/default.aspx ↗
http://www.elsevier.com/journals ↗ - DOI:
- 10.1097/j.pain.0000000000001155 ↗
- Languages:
- English
- ISSNs:
- 0304-3959
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 6333.795000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 9175.xml